These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20104120)

  • 1. Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing.
    Willig JH; Echevarria J; Westfall AO; Iglesias D; Henostroza G; Seas C; Mugavero MJ; Allison J; Paz J; Hernandez F; Tomatis C; Saag MS; Gotuzzo E
    J Acquir Immune Defic Syndr; 2010 Feb; 53(2):215-21. PubMed ID: 20104120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.
    Willig JH; Abroms S; Westfall AO; Routman J; Adusumilli S; Varshney M; Allison J; Chatham A; Raper JL; Kaslow RA; Saag MS; Mugavero MJ
    AIDS; 2008 Oct; 22(15):1951-60. PubMed ID: 18784459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of treatment-limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment.
    Phe T; Thai S; Veng C; Sok S; Lynen L; van Griensven J
    PLoS One; 2013; 8(3):e60206. PubMed ID: 23555926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
    Li T; Guo F; Li Y; Zhang C; Han Y; Lye W; He Y; Lu H; Xie J; Huang A; Li Y; Tang X; Wang H; Zhang T; Gao G; Lei J; Zhang X; Wu X; Sun Y; Bai J; Luo L; Wang H
    Chin Med J (Engl); 2014; 127(1):59-65. PubMed ID: 24384425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line antiretroviral drug discontinuations in children.
    Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
    PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
    Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes of initial differential antiretroviral regimens among HIV patients in Southwest China: comparison from an observational cohort study.
    Kang R; Luo L; Chen H; Zhu Q; Liao L; Xing H; Zhu J; Shen Z; Lan G; Tang Z; Shao Y; Yang W; Ruan Y
    BMJ Open; 2019 Mar; 9(3):e025666. PubMed ID: 30928945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abacavir versus Zidovudine-based regimens for treatment of HIV-infected children in resource limited settings: a retrospective cohort study.
    Mega TA; Usamo FB; Negera GZ
    BMC Pediatr; 2020 Mar; 20(1):99. PubMed ID: 32126978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana.
    Tetteh RA; Nartey ET; Lartey M; Mantel-Teeuwisse AK; Leufkens HG; Nortey PA; Dodoo AN
    BMC Public Health; 2015 Jun; 15():573. PubMed ID: 26092496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustainability of first-line antiretroviral regimens: findings from a large HIV treatment program in western Kenya.
    Braitstein P; Ayuo P; Mwangi A; Wools-Kaloustian K; Musick B; Siika A; Kimaiyo S
    J Acquir Immune Defic Syndr; 2010 Feb; 53(2):254-9. PubMed ID: 19745752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study.
    Ayele T; Jarso H; Mamo G
    AIDS Res Ther; 2017 Feb; 14(1):5. PubMed ID: 28143541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the utility of early laboratory monitoring of antiretroviral-induced haematological and hepatic toxicity in HIV-infected persons in Cameroon.
    Bekolo CE; Sonkoue C; Djidjou H; Bekoule PS; Kollo B
    BMC Infect Dis; 2014 Sep; 14():519. PubMed ID: 25253124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Didanosine: an updated review of its use in HIV infection.
    Perry CM; Noble S
    Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior antiretroviral therapy experience protects against zidovudine-related anaemia.
    Huffam SE; Srasuebkul P; Zhou J; Calmy A; Saphonn V; Kaldor JM; Ditangco R;
    HIV Med; 2007 Oct; 8(7):465-71. PubMed ID: 17760739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
    Cimoch PJ; Lavelle J; Pollard R; Griffy KG; Wong R; Tarnowski TL; Casserella S; Jung D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):227-34. PubMed ID: 9495222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries.
    Gibson RM; Nickel G; Crawford M; Kyeyune F; Venner C; Nankya I; Nabulime E; Ndashimye E; Poon AFY; Salata RA; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ
    Infect Dis Poverty; 2017 Dec; 6(1):163. PubMed ID: 29202874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
    Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
    Cochrane Database Syst Rev; 2000; (3):CD002038. PubMed ID: 10908523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.